Do you want to read an article? Please log in or register.
Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing
Multiple Sclerosis
RECOMMENDED
Related content
Multiple Sclerosis
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab
Mult Scler.
Mancinelli CR, Scarpazza C, Cordioli C, De Rossi N, Rasia S, Turrini MV, Capra R
doi: 10.1177/1352458520946017.
Multiple Sclerosis
Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis patients
Cytometry B Clin Cytom.
Puñet-Ortiz J, Hervás-García JV, Teniente-Serra A, Cano-Orgaz A, Mansilla MJ, Quirant-Sánchez B, Navarro-Barriuso J, Fernández-Sanmartín MA, Presas-Rodríguez S, Ramo-Tello C, Martínez-Cáceres EM
doi: 10.1002/cyto.b.21527.
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide
Clin Pharmacokinet.
Müller T, Foley P
doi: 10.1007/s40262-
Migraine and Headache
Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach
Cephalalgia
Cohen-Barak O, Radivojevic A, Jones A, Fiedler-Kelly J, Gillespie M, Brennan M, Gutman D, Rasamoelisolo M, Hallak H, Loupe P, Kessler Y, Ning X, Levi M, Ahn AH, Rabinovich-Guilatt L
doi: 10.1177/03331024211007789
Further Publications Neurology
Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial
JAMA
Vardeny O, Kim K, Udell JA, Joseph J, Desai AS, Farkouh ME, Hegde SM, Hernandez AF, McGeer A, Talbot HK, Anand I, Bhatt DL, Cannon CP, DeMets D, Gaziano JM, Goodman SG, Nichol K, Tattersall MC, Temte JL, Wittes J, Yancy C, Claggett B, Chen Y, Mao L, Havighurst TC, Cooper LS, Solomon SD, INVESTED Committees and Investigators.
doi: 10.1001/jama.2020.23649
Migraine and Headache
An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants
Headache.
McVige JW, Hogan RM, Shanahan CM, Amend DL, Ferger SM
doi: 10.1111/head.13922.
Multiple Sclerosis
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis
Mult Scler
Trojano M, Ramió-Torrentà L, Grimaldi LM, Lubetzki C, Schippling S, Evans KC, Ren Z, Muralidharan KK, Licata S, Gafson AR
doi: 10.1177/13524585211003020
Multiple Sclerosis
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
Neurology.
Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC
doi: 10.1212/
RECOMMENDED
Stroke
Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
JAMA.
Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, Yan B, Bush SJ, Thijs V, Scroop R, Simpson M, Brooks M, Asadi H, Wu TY, Shah DG, Wijeratne T, Zhao H, Alemseged F, Ng F, Bailey P, Rice H, de Villiers L, Dewey HM, Choi PMC, Brown H, Redmond K, Leggett D, Fink JN, Collecutt W, Kraemer T, Krause M, Cordato D, Field D, Ma H, O'Brien B, Clissold B, Miteff F, Clissold A, Cloud GC, Bolitho LE, Bonavia L, Bhattacharya A, Wright A, Mamun A, O'Rourke F, Worthington J, Wong AA, Levi CR, Bladin CF, Sharma G, Desmond PM, Parsons MW, Donnan GA, Davis SM, EXTEND-IA TNK Part 2 investigators.
doi: 10.1001/jama.2020.1511.